PATIENT REMINDER CARD

when receiving Humira
(for adults as well as paediatric patients)
It is necessary to show this card to every doctor or health care professional during each visit to a medical facility.

Patients shall keep this card on them for 5 months after their last dose of the treatment.
Humira contains an active ingredient adalimumab that reduces certain immune reactions. It is a medication that improves the course of some inflammatory diseases.

The active ingredient adalimumab is a human monoclonal antibody produced by cultured cells.
Severe adverse events can appear in patients receiving Humira, such as:

- **Infections** – Humira can cause the patient to become more susceptible to infections or it can worsen the infection they already suffer from. This includes infections such as common cold or severe infections such as tuberculosis.

- **Tumour disease** – The risk of developing certain types of tumour disease can be increased if you or your child is treated with Humira.

- **Nerve disorders (tingling, prickling or numbness)** – these can appear or if already existing they can worsen.

**Patients should inform their doctor if:**

- they have an infection or symptoms suggestive of infection (fever, injury, feeling tired, trouble with teeth, etc.),
- they are suffering from tuberculosis, or have been in close contact with a person suffering from tuberculosis,
- they are carriers of hepatitis B virus (HBV), have an active infection or think they are at risk of this infection,
- they have or have had tumour disease,
- they have the sensation of numbness or tingling or they are suffering from a nervous system disorder, such as multiple sclerosis.
Patients should seek immediate medical advice if they experience the following symptoms:

- **Allergic reactions** – chest tightness, trouble breathing or swallowing, swelling of the face or hands and feet, dizziness, severe rash;
- **Infection** – fever, chills, sweating, vomiting, diarrhoea, stomach ache, cough, burning on urination, skin inflammation, injury, muscle pain, trouble with teeth;
- **Tumour disease** – night sweating, swelling of glands in the neck, armpits or groins, weight loss, significant changes in the skin, severe itching.

This Patient Reminder Card does not list all possible adverse events that may occur. For more information about adverse events, please read the Humira leaflet or consult your doctor.

It is important that patients inform their doctor immediately about any unusual symptoms which occurred during treatment.
Patients should inform their doctor about:

- any changes in their health,
- any new drugs they are taking,
- any intervention or surgery they are planning.

VACCINATIONS:

- Patients on Humira may receive concurrent vaccinations, except for live vaccines.
- If Humira was received during pregnancy, it is important to inform pediatrician before the baby receives any vaccine. The baby should not receive a “live vaccine”, such as BCG (Bacillus Calmette–Guérin, used to prevent tuberculosis) within 5 months following the mother’s last adalimumab injection during pregnancy.

EXAMINATION:

The patient was examined for the incidence of ACTIVE or LATENT TUBERCULOSIS prior to the initiation of the treatment by HUMIRA.
<table>
<thead>
<tr>
<th>YEAR</th>
<th>Tuberculin skin test</th>
<th>Chest X-ray</th>
<th>Other (e.g. QFT)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Date of the first injection**: 
- **Dose**: 
- **Date of the last injection** (only if ending the treatment): 

*YEAR*
<table>
<thead>
<tr>
<th>Medications The Patient Is Taking:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
The medicine should be stored in a thermos-case at temperatures between +2 °C to +8 °C. Temperature should not vary. Medicine should not be exposed to light and must not freeze!

Name and address of the doctor:

..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................

E-mail: ................................................................................................................................. Tel. No.: ........................................................
If you or your child experiences any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet. You can also report side effects directly via the national reporting system.

More information about reporting can be found at: [http://www.olecich.cz/hlaseni-pro-suKL/nahlasit-nezadouci-ucinek](http://www.olecich.cz/hlaseni-pro-suKL/nahlasit-nezadouci-ucinek)

The postal address is State Institute for Drug Control, Pharmacovigilance Department, Šrobárova 48, Praha 10, 100 41, e-mail: [farmakovigilance@suKL.cz](mailto:farmakovigilance@suKL.cz).

It is appropriate to provide the specific trade mark and the batch number.

By reporting side effects, you can help provide more information on the safety of this medicine. This information can also be reported to the company AbbVie s.r.o., Tel. No. +420 233 098 111, e-mail: [safety-cz@abbvie.com](mailto:safety-cz@abbvie.com).